{"filings":[{"id":95329,"accession_number":"0001628280-26-032073","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"10x Genomics Q1 2026 net loss narrows to $13.5M; launches Atera platform","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $150.8M (-3% YoY); +9% excluding $16.8M one-time license/royalty in Q1 2025.","Gross margin 70% vs 68%; operating loss $17M vs $39.3M prior year.","Net loss $13.5M vs $34.4M; cash $539.8M (+$112.9M YoY).","Launched Atera spatial whole-transcriptome platform; shipping expected H2 2026.","FY 2026 revenue guidance maintained at $600M-$625M (0-4% growth ex-2025 one-time)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":150843000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108293,"accession_number":"0001628280-26-007673","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"10x Genomics Q4 revenue $166M (+1% YoY); FY26 guidance $600-625M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $166.0M (+1% YoY); FY25 $642.8M (+5%), ex-settlements $598.7M (-2%).","Q4 net loss $16.3M vs $49.0M loss YoY; FY25 net loss $43.5M vs $182.6M loss YoY.","Operating expenses down 18% Q4 and 17% FY; gross margin 68% Q4 and 69% FY.","FY2026 revenue guidance $600-625M (0-4% growth ex-2025 settlements).","Cash and equivalents $523.4M at year-end, up $130M vs prior year."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":642823000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108292,"accession_number":"0001628280-26-001808","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"10x Genomics reports preliminary Q4 rev $166M (+1% YoY); FY 2025 rev $642.8M incl. $44.1M settlements","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 consumables rev $141.7M (+6% YoY); Spatial consumables up 14% YoY to $41.0M.","Q4 instruments rev $15.5M (-36% YoY); Single Cell instruments down 44% YoY.","Full year rev ex-settlements $598.7M (-2% YoY); instruments rev down 39%.","Cash & securities ~$520M at Dec 31, 2025; cumulative instruments: >6,400 Chromium, >1,500 Spatial.","Single Cell consumables reactions sold increased >20% vs prior year."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":642823000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124740,"accession_number":"0001628280-25-052154","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"10x Genomics CLO Eric Whitaker retiring Jan 1, 2026; Randy Wu named General Counsel","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric Whitaker to retire as Chief Legal Officer effective Jan 1, 2026, will remain as Strategic Counsel with reduced compensation.","Dr. Randy Wu, VP of IP and Litigation, appointed General Counsel and Secretary effective Jan 1, 2026.","Wu joined 10x in August 2016; holds Ph.D. in Biophysics from UCSF and J.D. from Stanford Law School.","CEO Serge Saxonov praised Whitaker's eight-year tenure including IPO and legal strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124739,"accession_number":"0001770787-25-000058","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"10x Genomics Q3 revenue $149M (-2% YoY); guides Q4 $154-158M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $149.0M in Q3 2025, down 2% YoY; gross margin 67% vs 70% prior year.","Operating loss improved to $32.2M from $41.5M; net loss $27.5M vs $35.8M.","Cash and marketable securities $482.1M, up $35M sequentially.","Q4 2025 revenue guidance $154-158M (midpoint 6% decline YoY, 5% sequential growth).","Launched next-gen Chromium Flex and Xenium Protein spatial multiomic workflow."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":476793000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141437,"accession_number":"0001770787-25-000048","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"10x Genomics Q2 revenue down 5% ex-litigation; net income $34.5M; acquires Scale Bio for $30M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $172.9M including $27.3M patent settlement; adjusted revenue $145.6M (-5% YoY).","GAAP net income $34.5M vs net loss $37.9M YoY; operating income $30.1M.","Gross margin 72% vs 68% YoY; ex-license/royalty gross margin 67%.","Q3 2025 revenue guidance $140M-$144M, reflecting ~$4M China pull-forward.","Agreement to acquire Scale Biosciences for $30M upfront cash/stock plus milestone contingent consideration."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":327791000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159252,"accession_number":"0001770787-25-000040","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"10x Genomics stockholders re-elect Sri Kosaraju and Shehnaaz Suliman as Class III directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Kosaraju received 189,313,724 votes for and 7,243,542 against; Suliman 168,973,468 for and 27,595,026 against.","Ratification of Ernst & Young as independent auditor for FY2025 passed with 215,766,816 votes for.","Non-binding advisory vote on named executive officer compensation approved with 164,321,765 votes for.","108,937,350 shares present or represented by proxy, representing 87.7% of eligible votes, constituting a quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159251,"accession_number":"0001770787-25-000035","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"10x Genomics settles patent litigation with Bruker; to receive $68M upfront plus royalties","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settled all patent litigation with Bruker (formerly NanoString) regarding spatial biology platforms; all claims dismissed with prejudice.","10x expects $68M in upfront nonrefundable payments, paid in equal quarterly installments with interest from Q3 2025 to Q2 2026.","Ongoing royalty payments on licensed products and services for the life of the licensed patents.","Litigation began in 2021–2022 targeting NanoString's GeoMx and CosMx spatial platforms; Bruker assumed liabilities in May 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159250,"accession_number":"0001770787-25-000031","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","2.05","9.01"],"status":"ready","headline":"10x Genomics revenue ex-settlement falls 2% YoY; cuts 8% workforce, withdraws FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $154.9M incl $16.8M patent settlement; ex-settlement $138.1M, down 2% YoY.","Net loss $34.4M vs $59.9M YoY; operating loss $39.3M, improved from $61.5M.","Cutting ~8% of global workforce; expects $5.5-6.5M severance in Q2 2025.","Withdraws full-year 2025 guidance citing US academic/government funding uncertainty.","Q2 2025 revenue guidance $138-142M (ex-settlement), 1% sequential growth at midpoint."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":154883000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177687,"accession_number":"0001770787-25-000011","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"10x Genomics Q4 revenue down 10% YoY to $165M; FY2024 net loss $182.6M; guidance ~flat","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue $165.0M (-10% YoY); full year $610.8M (-1% YoY).","Q4 operating loss $49.8M, net loss $49.0M (unchanged YoY).","Full year 2024 net loss $182.6M, improved from $255.1M loss in 2023.","FY2025 revenue guidance $610M-$630M (0-3% growth); midpoint implies double-digit growth for Chromium and spatial.","Cash and securities $393.4M; launched Billion Cells Project with CZI and Ultima Genomics."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":610785000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177686,"accession_number":"0001770787-25-000003","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"10x Genomics reports preliminary Q4 2024 revenue of $165M, down 10% YoY but up 9% sequentially","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 revenue ~$610.8M (-1% YoY); Q4 revenue ~$165M (-10% YoY, +9% sequentially).","Instruments Q4 revenue $24.4M (-37% YoY); consumables $133.5M (-5% YoY); services $7.1M (+35% YoY).","Cumulative instruments deployed >7,000; cash and equivalents ~$393M.","Preliminary and unaudited; subject to adjustment after year-end close."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":610785000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194406,"accession_number":"0001770787-24-000071","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"10x Genomics Q3 revenue $151.7M (-1% YoY); cuts FY2024 revenue guidance to $595-605M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $151.7M, down 1% YoY; net loss improved to $35.8M from $93.0M.","FY2024 revenue guidance lowered to $595-605M from prior $640-660M (3% decline YoY midpoint).","CEO cites greater-than-anticipated disruption from sales restructuring and cautious spending.","Board member Mathai Mammen resigned effective Oct 24, 2024 due to professional time commitments.","Launched GEM-X Flex, GEM-X Universal Multiplex, and Chromium Xo instruments."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":445764000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194405,"accession_number":"0001770787-24-000064","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2024-10-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"10x Genomics preliminary Q3 revenue $151.7M, down 1% YoY; instruments revenue falls 46%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of ~$151.7M, down 1% YoY; instruments revenue $19.1M (-46%), consumables $126.2M (+10%), services $6.4M (+48%).","Americas revenue $87.8M (-11% YoY); EMEA $37.9M (+18%); APAC $26.0M (+15%).","CEO cites commercial reorganization disruption and cautious customer spending on capital equipment as key headwinds.","Cash and equivalents ~$398M as of Sept 30; full-year 2024 guidance to be discussed on October 29 earnings call."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":445764000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210732,"accession_number":"0001770787-24-000058","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","5.02","8.01","9.01"],"status":"ready","headline":"10x Genomics reports Q2 revenue $153.1M (+4% YoY), guides FY24 down to $640-660M; CFO resigns, Taich appointed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $153.1M, +4% YoY; net loss $37.9M vs $62.4M loss in prior year.","Operating expenses down 10% to $146.0M; gross margin flat at 68%.","Full year 2024 revenue guidance lowered to $640-660M from $670-690M (3-7% growth).","CFO Justin McAnear resigns effective Aug 30; Adam Taich appointed CFO effective Aug 12.","Mennah Moustafa named Chief Commercial Officer effective Aug 1."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":294110000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210731,"accession_number":"0001770787-24-000048","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2024-07-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"10x Genomics appoints Sarah A. Teichmann to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Effective July 10, 2024; Class II director with term expiring at 2027 annual meeting.","Teichmann is Chair in Stem Cell Medicine at University of Cambridge and co-chair of Human Cell Atlas.","She receives $55,000 annual cash retainer plus initial RSU grant valued at $400,000.","Annual RSU grant of $215,000 on annual meeting date; both grants vest over time with continued service.","Also serves as VP at GSK and CSO at EnsoCell Therapeutics; brings genomics and leadership expertise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229115,"accession_number":"0001770787-24-000044","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"10x Genomics appoints Alan V. Mateo to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alan V. Mateo appointed as Class II director effective June 18, 2024, term until 2027 annual meeting.","Mateo previously Executive VP Global Sales at Veeva Systems, executive roles at Medidata Solutions and PeopleSoft.","Receives $55k annual cash retainer, $400k initial RSU grant (July 31, 2024), and $215k annual RSU grant.","Compensation includes standard indemnification agreement; eligible for additional committee service retainers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229114,"accession_number":"0001770787-24-000040","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"10x Genomics annual meeting results: director elected, auditor ratified, bylaw amendment fails","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Director Kimberly J. Popovits elected with 198.6M votes for, 18.7M against.","Ernst & Young ratified as auditor with 228.8M votes for.","Bylaw amendment to let board amend without stockholder approval defeated (112.7M for, 104.5M against).","Non-binding executive compensation approved with 180.8M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229113,"accession_number":"0001770787-24-000035","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"10x Genomics Q1: revenue up 5% to $141M, net loss widens to $59.9M; guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $141.0M (+5% YoY); gross margin 66% vs 73% due to product mix shift to Xenium instruments.","Net loss widened to $59.9M from $50.7M; operating loss $61.5M vs $52.0M.","FY2024 revenue guidance maintained at $670M-$690M, representing 8-12% growth over FY2023.","Shipped Visium HD for spatial discovery, GEM-X single cell technology, and Xenium cell segmentation products.","Operating expenses up 3% to $154.4M; stock-based compensation declined to $36.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":141006000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247719,"accession_number":"0001770787-24-000015","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2024-02-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"10x Genomics Q4 revenue up 18% to $184M but net loss widens to $49M; FY2024 guidance 8-12% growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue $184.0M (+18% YoY); FY2023 revenue $618.7M (+20% YoY).","Q4 gross margin 63% vs 76% YoY due to higher mix of Spatial instruments.","Q4 operating loss $55.2M (vs $23.1M), including $38.9M stock-based comp and $19.6M in-process R&D expense.","Full year 2023 net loss $255.1M, widened from $166.0M in 2022.","FY2024 revenue guidance $670M-$690M (8-12% growth); cumulative instruments sold reached 5,966."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":618727000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247718,"accession_number":"0001770787-24-000007","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2024-01-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CCO James Wilbur to depart 10x Genomics on Feb 1, 2024; gets severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James Wilbur, Chief Commercial Officer, leaving effective Feb 1, 2024; no disagreement with management.","Severance: six months base salary plus one-time COBRA payment of $14,335.","No 2023 annual performance bonus for Wilbur.","Departure not related to company's operations, financial statements, or policies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247717,"accession_number":"0001770787-24-000004","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"10x Genomics reports preliminary Q4 revenue of $184M, up 18% YoY; instruments up 72%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2023 revenue ~$184.0M, 18% growth over prior year; full-year revenue ~$618.7M, up 20%.","Q4 instruments revenue ~$38.4M (+72% YoY), driven by Spatial ($27.2M) and Chromium ($11.1M).","Q4 consumables revenue ~$140.3M (+7% YoY); services revenue ~$5.3M (+129% YoY).","Cumulative instruments sold exceeded 5,900 as of year-end 2023, including over 5,150 Chromium, 500 Visium, 250 Xenium.","Final audited results expected in February 2024 earnings call; preliminary figures subject to adjustment."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":618727000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}